Foremost among potential therapeutic targets in pancreatic cancer stand cancer’s most frequently mutated oncogene family, the RAS genes [203]; and the “guardian of the genome” TP53 tumor suppressor gene. Here, TP53 is linked to familial pancreatic carcinoma.